Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters

Database
Country/Region as subject
Language
Journal subject
Affiliation country
Publication year range
1.
Am J Gastroenterol ; 119(4): 655-661, 2024 Apr 01.
Article in English | MEDLINE | ID: mdl-37975609

ABSTRACT

INTRODUCTION: Whether 10-day short-course vonoprazan-amoxicillin dual therapy (VA-dual) is noninferior to the standard 14-day bismuth-based quadruple therapy (B-quadruple) against Helicobacter pylori eradication has not been determined. This trial aimed to compare the eradication rate, adverse events, and compliance of 10-day VA-dual regimen with standard 14-day B-quadruple regimen as first-line H. pylori treatment. METHODS: This prospective randomized clinical trial was performed at 3 institutions in eastern China. A total of 314 treatment-naive, H. pylori -infected patients were randomly assigned in a 1:1 ratio to either 10-day VA-dual group or 14-day B-quadruple group. Eradication success was determined by 13 C-urea breath test at least 4 weeks after treatment. Eradication rates, adverse events, and compliance were compared between groups. RESULTS: Eradication rates of VA-dual and B-quadruple groups were 86.0% and 89.2% ( P = 0.389), respectively, by intention-to-treat (ITT) analysis; 88.2% and 91.5% ( P = 0.338), respectively, by modified ITT analysis; and 90.8% and 91.3% ( P = 0.884), respectively, by per-protocol (PP) analysis. The efficacy of the VA-dual remained noninferior to B-quadruple therapy in all ITT, modified ITT, and PP analyses. The incidence of adverse events in the VA-dual group was significantly lower compared with that in the B-quadruple group ( P < 0.001). Poor compliance contributed to eradication failure in the VA-dual group ( P < 0.001), while not in the B-quadruple group ( P = 0.110). DISCUSSION: The 10-day VA-dual therapy provided satisfactory eradication rates of >90% (PP analysis) and lower rates of adverse events compared with standard 14-day B-quadruple therapy as first-line H. pylori therapy. TRAIL REGISTRATION NUMBER: ChiCTR2300070100.


Subject(s)
Helicobacter Infections , Helicobacter pylori , Pyrroles , Sulfonamides , Humans , Amoxicillin/therapeutic use , Bismuth/therapeutic use , Bismuth/adverse effects , Anti-Bacterial Agents , Helicobacter Infections/drug therapy , Prospective Studies , Drug Therapy, Combination , Medication Adherence , Treatment Outcome , Proton Pump Inhibitors/adverse effects
2.
World J Gastroenterol ; 23(43): 7756-7764, 2017 Nov 21.
Article in English | MEDLINE | ID: mdl-29209116

ABSTRACT

AIM: To gain knowledge of xanthelasma, a large population-based study was conducted. METHODS: Patients who underwent upper gastrointestinal endoscopy at the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China during Jan 2009 to Nov 2016 were included. General characteristics as well as clinical data were collected, including blood routine, serum biochemical analysis, endoscopic findinds, histological evaluation and comorbiditie. Statistical analyses was performed using SPSS 20.0 software for Windows (IBM Inc., Chicago, IL, United States) using Student's t-test, Mann-Whitney U test, χ2 test, univariable and multivariable logistic analysis. 2-tailed P value less than 0.05 was considered to be statistically significant. RESULTS: A total of 176006 endoscopies were retrieved and we included 1370 xanthelasma participants (703 men, 667 women) in this study. Prevalence of xanthelasma was 0.78% with average age of 56.6 ± 11.2 years. Chief complaint of xanthelasma consisted abdominal pain (24.2%), up-abdominal discomfort (14.1%), abdominal distention (10.1%), dyspepsia (9.1%), et al. Most xanthelasma occurred as single lesion in gastric antrum. Xanthelasma patients witnessed higher Helicobacter pylori (H. pylori) infection rate, more of other gastric lesions including atrophy, intestinal metaplasia and dysplasia (P < 0.01). In xanthelasma patients, serum carcinoembryonic antigen, triglyceride, fasting glucose, neutrophil, neutrophil-to-lymphocyte ratio were significantly higher, and high density lipoprotein-cholesterol, lymphocyte was lower (P < 0.05). Xanthelasma accompanied with more fatty liver disease and hepatic cyst, but fewer gallbladder polyp (P < 0.05). In logistic regression, it revealed that fasting plasma glucose (OR = 3.347, 1.170-9.575, P < 0.05), neutrophil (OR = 1.617, 1.003-2.605, P < 0.05), and carcinoembryonic antigen (OR = 2.011, 1.236-3.271, P < 0.01) were all independent risk factors in xanthelasma. CONCLUSION: Current study described a large xanthelasma cohort in Chinese population, revealed its relationship with H. pylori infection, carcinogenesis, metabolic dysfunction and inflammation as well.


Subject(s)
Gastric Mucosa/pathology , Helicobacter Infections/epidemiology , Pyloric Antrum/pathology , Stomach Diseases/epidemiology , Xanthomatosis/epidemiology , Adult , Aged , Atrophy/blood , Atrophy/diagnostic imaging , Atrophy/epidemiology , Atrophy/pathology , Blood Glucose/analysis , Carcinoembryonic Antigen/blood , China/epidemiology , Female , Gastric Mucosa/diagnostic imaging , Gastroscopy , Helicobacter Infections/blood , Helicobacter Infections/diagnostic imaging , Helicobacter Infections/microbiology , Helicobacter pylori/isolation & purification , Humans , Male , Metaplasia/blood , Metaplasia/diagnostic imaging , Metaplasia/epidemiology , Metaplasia/pathology , Middle Aged , Non-alcoholic Fatty Liver Disease/blood , Non-alcoholic Fatty Liver Disease/diagnostic imaging , Non-alcoholic Fatty Liver Disease/epidemiology , Non-alcoholic Fatty Liver Disease/pathology , Prevalence , Pyloric Antrum/diagnostic imaging , Retrospective Studies , Risk Factors , Stomach Diseases/blood , Stomach Diseases/diagnostic imaging , Stomach Diseases/microbiology , Xanthomatosis/blood , Xanthomatosis/diagnostic imaging , Xanthomatosis/microbiology
SELECTION OF CITATIONS
SEARCH DETAIL